ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Buprenorphine Pharmacology Related to Addiction Treatment - 18

This study has been completed.

Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
University of Vermont
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00000236
  Purpose

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.


Condition Intervention Phase
Opioid-Related Disorders
Drug: Buprenorphine/naloxone
Phase II

Drug Information available for:   Naloxone    Naloxone hydrochloride    Buprenorphine    Buprenorphine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment
Official Title:   Buprenorphine Pharmacology Related to Addiction Treatment

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Opioid agonist effects
  • Opiate withdrawal
  • Psychological changes in: pupil diameter, blood pressure, heart rate, respiration

Estimated Enrollment:   0

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Please contact site for information.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000236

Locations
United States, Vermont
Treatment Research Center    
      Burlington, Vermont, United States, 05401

Sponsors and Collaborators

Investigators
Principal Investigator:     Warren Bickel, Ph.D.     University of Vermont    
  More Information


Study ID Numbers:   NIDA-06969-18, R01-06969-18
First Received:   September 20, 1999
Last Updated:   August 16, 2005
ClinicalTrials.gov Identifier:   NCT00000236
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Buprenorphine
Behavior, Addictive
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Opioid-Related Disorders
Naloxone

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions
Analgesics, Opioid

ClinicalTrials.gov processed this record on December 03, 2008




Links to all studies - primarily for crawlers